Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Xpovio’s Solid Tumor Debut Faces Likely Three-Year Delay

Executive Summary

Karyopharm will conduct another trial of the drug in p53 wild-type endometrial cancer after the FDA said SIENDO data were insufficient for approval.

You may also be interested in...



Finance Watch: No New IPOs, But Two Firms Take The SPAC Route

Public Company Edition: NewAmsterdam grossed $328m in its SPAC merger, while Liminatus may raise up to $316m in a new SPAC deal. Also, Intellia and Iveric grossed $300m each in follow-on offerings, bluebird sold a PRV for $102m and MEI ends zandelisib development resulting in layoffs.

Subgroup Could Give Xpovio Focused Commercial Opportunity In Endometrial Cancer

Karyopharm’s Phase III SIENDO study showed what analysts called a “modest” progression-free survival improvement overall, but a fourfold improvement in patients with wild-type p53.

Esperion Hopes CVOT Will Help Drive Nexletol/Nexlizet’s Market Uptake

The drugs have been slow to catch on since approval more than two years ago, but results showing reduction in cardiovascular events could help it gain traction.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145988

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel